US FDA Faces Down Complex Combo Products, Fires Up Oncology Center Of Excellence
Executive Summary
FDA officials discuss difficulties dealing with complex combination products, the future of the agency's product centers, and promotion of industry collaboration at the Drug Information Association's annual meeting.
You may also be interested in...
US FDA Device Funding Would Leap By 26% In 2019 Under Trump Budget Proposal
US FDA Device Center program funding would see a $131m increase under the Trump administration's budget proposal, which prioritizes "speeding innovations" in medical devices and other products the agency regulates, and closely examining what regulations need to be revised, updated or eliminated.
Companies Want New US FDA Council To Help Resolve Inter-Agency Combo Product Disputes
A range of topics were raised in feedback provided by industry groups to FDA about what the priorities should be for the agency's new Combination Products Policy Council, but addressing inter-center disagreements was a repeat concern. Also raised: misaligned communication policies; pediatric combo-product reviews; and implementation of the 21st Century Cures Act.
US FDA Likely Not 'Significant', Could Be Mostly Spared From Trump's Regulation-Slashing Order
But even though executive order that requires regulatory off sets may only have limited application to FDA, limited, experts warn that it still could prove extremely unwieldly to implement.